

**Notice Declaring Intention to be Qualified under  
National Instrument 44-101 (“NI 44-101”)  
Short Form Prospectus Distributions**

December 10, 2020

**To: Ontario Securities Commission**

**And To: British Columbia Securities Commission  
Alberta Securities Commission**

Revive Therapeutics Ltd. (the “Issuer”) intends to be qualified to file a short form prospectus under NI 44-101. The Issuer acknowledges that it must satisfy all applicable qualification criteria prior to filing a preliminary short form prospectus. This notice does not evidence the Issuer’s intent to file a short form prospectus, to enter into any particular financing or transaction or to become a reporting issuer in any jurisdiction. This notice will remain in effect until withdrawn by the Issuer.

**Revive Therapeutics Ltd.**

*“Michael Frank”*

Michael Frank  
Chief Executive Officer